REG - IXICO plc - Result of AGM

IXICOAnnouncement

21/01/2021 11:05

RNS Number : 4748M
  
IXICO plc
  
21 January 2021
  
 

 
 
IXICO plc
("IXICO" or the "Company")
 
Results of AGM
 
IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
 




Resolution


Description


Total Votes For


% Votes


Total Votes Against


Withheld




1


Reports and Accounts
 


30,185,052


99.95%
 


15,600


400




2


Re-election of Directors


 


 


 


 




Re-election of Mark Warne
 


30,185,152
 


99.95%


15,900
 


0
 




Re-election of John Bradshaw


30,185,452


99.95%


15,600


0




3


Re-appointment of Auditors
 


30,065,960


99.57%


128,100


6,992




4


Allotment of Securities
 


30,180,960


99.94%


17,100


2,992




5


Disapply Pre-Emption Provisions
 


30,180,010


99.94%


18,050


2,992




6


Amendment of rule 3.6.1 of the Company's 2014 EMI Share Option Plan
 


30,165,610


99.89%


33,350


1,992




 
For further information please contact:
 




IXICO plc


+44 (0)20 3763 7498




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 




 


 




Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0)20 7397 8900




Giles Balleny / Max Gould (Corporate Finance)


 




Michael F Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


+44 (0)20 7933 8780 




Paul McManus / Lianne Cawthorne /


IXICO@walbrookpr.com




Alice Woodings


 




 


 


 


 


 




 
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients. 
 
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGDKDBPKBKDFDB